Evaluation And Intervention Of Quetiapine Fumarate For Schizophrenia Patients With Depressive Symptoms

Part I : Reliability and Validity of the Chinese version of Calgary Depression Scale for SchizophreniaObjective: To examine the reliability and validity of the Chinese version of Calgary Depression Scale for Schizophrenia (CDSS-C).Methods: CDSS-C, translated by ZHANG Hong-yan, was administrated to total of 100 Schizophrenics, The Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale (HAMD-24) and Treatment Emergent Symptom Scale (TESS) were also administrated at the same time.Results: In CDSS-C,①The Cronbachαcoefficient were 0.798-0.810, the Spearman- Brown split reliability were 0.694-0.727, and the test-retest reliability were 0.638-0.831.②The 9 items were divided into 2 dimensions: depression experience and self-assessment.③The CDSS-C total scores had significant correlations with the scores of HAMD-24 (r=0.76) and PANSS-G6 (r=0.70).④The cut-off point was≥6.Conclusion: The CDSS-C has acceptable psychometrics properties in reliability and validity. Part II : A Randomized and Controlled Study about Quetiapine Fumarate and Haloperidol in the Treatment of Depressive Symptoms in SchizophreniaObjective: To examine the incidence and the characteristics of the depressive symptoms in schizophrenia, then compare the effect of Quetiapine Fumarate and Haloperidol to the depressive symptoms in schizophrenia.Methods: 70 schizophrenic patients who met DSM-IV criteria for schizophrenia were randomly divided into two groups of Quetiapine Fumarate and Haloperidol. They would be under treatment for four weeks. The clinical effect and side effect were evaluated by the Chinese version of Calgary Depression Scale for Schizophrenia (CDSS-C), The Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale(CGI) and the Treatment Emergent Symptom Scale (TESS) before and after treatments for 1,14,28 days. At the same time, we undertook the physical and laboratory examination and record the adverse events.Results:①There were 21 patients whose score of CDSS-C was more than 6 among the 70 schizophrenia patients, so the incidence of depression was 30%. The score were higher in 2, 3, 4, 5 items than the others.②Finally, there were 58 patients who completed the study. 8 patients in Quetiapine Fumarate group and 4 in Haloperidol group discontinuated from the study.③At the end of the study, There were significant differences between the two groups in the efficacy to depressive symptoms CP=0.000), the total score of CDSS-C of Quetiapine group was lower than that of Haloperidol group (P=0.027) , the score of CDSS-C in Quetiapine group reduced significantly more than that in Haloperidol group at the 14 and 28 day (P=0.000 and 0.001) , but there were no differences between the two groups in the efficacy to psychiatric symptoms (P =0.481) .④The severity of side effect were higher in Haloperidol group than that in Quetiapine group, There were significant differences between the two groups in the TESS score at different time. Haloperidol had improved more plasma prolactin level than that of Quetiapine.Conclusion:①The incidence of the depressive symptoms in schizophrenia is high.②Accompanied hopelessness, low self-assessment is the character of the depressive symptoms in schizophrenia.③Compared to Haloperidol, Quetiapine Fumarate is more effective and safe in treatment of the depressive symptoms in schizophrenia and is feasible to attempt to use in the clinic.